利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.02 秒)

    Antithrombotic method
    6.
    发明授权
    Antithrombotic method 失效
    抗血栓方法

    公开(公告)号：US4342759A

    公开(公告)日：1982-08-03

    申请号：US179460

    申请日：1980-08-19

    申请人： Thomas A. Purcell ,  Braham Shroot ,  Daniel Galtier

    发明人： Thomas A. Purcell ,  Braham Shroot ,  Daniel Galtier

    IPC分类号： A61K31/395 ,  C07D295/215 ,  A61K31/54 ,  A61K31/495

    CPC分类号： C07D295/215 ,  A61K31/395

    摘要： A method of treating a patient susceptible to thrombosis is provided which comprises treating the said patient with a compound of the formula ##STR1## wherein R' is H or CH.sub.3R is a ##STR2## radical in which Z is 0, S, SO, SO.sub.2 or NR.sub.1, R.sub.1 being H, C.sub.6 H.sub.5, CH.sub.3, CONR.sub.2 R.sub.3, COOR.sub.2, COR.sub.2 or SO.sub.2 R.sub.2, where R.sub.2 and R.sub.3 are, independently, H, C.sub.1-4 alkyl, C.sub.6 H.sub.5 or CF.sub.3.

    摘要翻译： 提供一种治疗易患血栓形成的患者的方法，其包括用下式化合物治疗所述患者：其中R'为H或CH 3 R为其中Z为0，S，SO， SO 2或NR 1，R 1是H，C 6 H 5，CH 3，CONR 2 R 3，COOR 2，COR 2或SO 2 R 2，其中R 2和R 3独立地是H，C 1-4烷基，C 6 H 5或CF 3。

    Pyridone derivatives, their preparation and their use as synthesis intermediates
    7.
    发明授权
    Pyridone derivatives, their preparation and their use as synthesis intermediates 失效
    吡啶酮衍生物，其制备及其作为合成中间体的用途

    公开(公告)号：US06252082B1

    公开(公告)日：2001-06-26

    申请号：US09341574

    申请日：1999-07-14

    申请人： Gilbert Lassalle ,  Patrice Bellevergue ,  Jean-Claude Bourbier ,  Daniel Galtier ,  Valérie Martin

    发明人： Gilbert Lassalle ,  Patrice Bellevergue ,  Jean-Claude Bourbier ,  Daniel Galtier ,  Valérie Martin

    IPC分类号： C07D21186

    CPC分类号： C07D213/64 ,  C07D213/69 ,  C07D213/70 ,  C07D213/71 ,  C07D213/73 ,  C07D213/75 ,  C07D213/76 ,  C07D409/06

    摘要： The invention concerns compounds of formula (I) in which: R is —NO2 or —NHR3, R3 being hydrogen, —COR4 (R4 selected among (C1-C4) alkyl, aryl and aryl (C1-C4) alkyl, —COOR5 (R5 selected among (C1-C4) alkyl and aryl (C1-C4) alkyl), —CONHR6 or SO2R6 (R6 selected among (C1-C5) alkyl, aryl and aryl(C1-C4) alkyl), —SO2NR7R8 (R7 and R8 independently of each other represent hydrogen or (C1-C4) alkyl or form with the nitrogen atom a morpholine group), aryl (C1-C4) alkyl, R1 is a (C1-C4) alkyl group linear or branched, cyclo (C3-C8) alkyl, aryl optionally substituted, aryl (C1-C4) alkyl optionally substituted, heteroaryl, R2 is a hydrogen atom, a (C1-C4) alkyl or arylmethyl group, X is an oxygen or sulphur atom, a —CH2—, —SO2 or —NR1— group and Y is a hydrogen atom or (C1-C6) alkyl. The invention is applicable to synthesis intermediates.

    摘要翻译： 本发明涉及式（I）化合物，其中R为-NO 2或-NHR 3，R 3为氢，-COR 4（R 4选自（C 1 -C 4）烷基，芳基和芳基（C 1 -C 4）烷基，-COOR 5（ （C1-C4）烷基和（C1-C4）烷基），-CONHR6或SO2R6（R6选自（C1-C5）烷基，芳基和芳基（C1-C4）烷基），-SO2NR7R8（R7和 相互独立地表示氢或（C1-C4）烷基或与氮原子形成吗啉基），芳基（C1-C4）烷基，R1是直链或支链的（C1-C4）烷基，环（C3 任选取代的芳基（C 1 -C 4）烷基，杂芳基，R 2是氢原子，（C 1 -C 4）烷基或芳基甲基，X是氧或硫原子，-CH 2 - ，-SO2或-NR1-基，Y为氢原子或（C1-C6）烷基，本发明适用于合成中间体。

    1-[2-(arylsulphonylamino)-1-oxoethyl]piperidine derivatives, their preparation and their therapeutic application
    8.
    发明授权
    1-[2-(arylsulphonylamino)-1-oxoethyl]piperidine derivatives, their preparation and their therapeutic application 失效
    1- [2-（芳基磺酰基氨基）-1-氧代乙基]哌啶衍生物，其制备及其治疗应用

    公开(公告)号：US5453430A

    公开(公告)日：1995-09-26

    申请号：US37972

    申请日：1993-03-29

    申请人： Gilbert Lassalle ,  Thomas Purcell ,  Daniel Galtier ,  Paul H. Williams ,  Frederic Galli

    发明人： Gilbert Lassalle ,  Thomas Purcell ,  Daniel Galtier ,  Paul H. Williams ,  Frederic Galli

    IPC分类号： A61K31/415 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/47 ,  A61P7/02 ,  C07D233/54 ,  C07D233/64 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07K5/078 ,  C07D403/14

    CPC分类号： C07D233/64 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07K5/06139

    摘要： Compounds of formula (I) ##STR1## wherein R represents a ##STR2## group in which R.sub.2 is a hydrogen atom, a (C.sub.1 -C.sub.4)alkoxycarbonyl group, a carboxylic group, a sodium carboxylate group, a --CH.sub.2 OR.sub.4 group R.sub.4 being a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group or a (C.sub.1 -C.sub.4)acyl group, an amide group of the formula --CONR.sub.5 R.sub.6, or a --CN.sub.4 R.sub.5 group, R.sub.5 being a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group and R.sub.6 being a hydrogen atom, a (C.sub.1 -C.sub.4)alkyl group, a hydroxy group or a (C.sub.1 -C.sub.4)alkoxy group, and R.sub.3 is a (C.sub.1 -C.sub.4)alkyl group,R.sub.1 represents either a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group,X represents either a sulphur atom, an oxygen atom or a methylene group, n=1 or 2 andAr represents either a naphthalen-1-yl group substituted by a di(C.sub.1 -C.sub.4)alkylamino group, or a 6,7-di(C.sub.1 -C.sub.4)alkoxynaphthalen-1-yl group, or a quinolin-8-yl group substituted at 3 by a (C.sub.1 -C.sub.4)alkyl group, or a 1,2,3,4-tetrahydroquinolin-8-yl group substituted at 3 by a (C.sub.1 -C.sub.4)alkyl, or a 1H-indazol-7-yl group and pharmaceutically acceptable organic or inorganic salts thereof.Application in therapy.

    摘要翻译： 式（I）化合物其中R表示其中R 2为氢原子，（C 1 -C 4）烷氧基羰基，羧基，羧酸钠基团，-CH 2 OR 4基团 R4是氢原子或（C1-C4）烷基或（C1-C4）酰基，式-CONR5R6的酰胺基或-CN4R5基，R5是氢原子或（C1-C4） ）烷基，R6为氢原子，（C1-C4）烷基，羟基或（C1-C4）烷氧基，R3为（C1-C4）烷基，R1为氢原子 或（C1-C4）烷基，X表示硫原子，氧原子或亚甲基，n = 1或2，Ar表示被二（C1-C4）烷基取代的萘-1-基， 烷基氨基或6,7-二（C1-C4）烷氧基萘-1-基或在3个被（C1-C4）烷基取代的喹啉-8-基）或1,2,3 （C 1 -C 4）烷基取代的4-四氢喹啉-8-基，或1H-吲唑-7-基和药学上可接受的组 其酸性或无机盐。 应用于治疗。